Ignite Creation Date:
2025-12-25 @ 2:49 AM
Ignite Modification Date:
2025-12-26 @ 1:30 AM
Study NCT ID:
NCT06334133
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2024-03-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000654432', 'term': 'TTP399'}, {'id': 'C494814', 'term': 'BID protein, human'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 150}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-06-14', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2026-10', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-22', 'studyFirstSubmitDate': '2024-03-13', 'studyFirstSubmitQcDate': '2024-03-20', 'lastUpdatePostDateStruct': {'date': '2025-12-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2024-03-27', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-09', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in incidence of Level 2 or Level 3 hypoglycemia', 'timeFrame': '26 weeks', 'description': 'Number of events of Level 2 or Level 3 hypoglycemia in participants on cadisegliatin vs placebo.'}], 'secondaryOutcomes': [{'measure': 'To assess the change in HbA1c', 'timeFrame': '26 weeks', 'description': 'Change from baseline in HbA1c in participants on cadisegliatin vs placebo.'}, {'measure': 'To assess the effects of treatment on CGM-based metrics for glycemic control', 'timeFrame': '26 weeks', 'description': 'Change from baseline for time in, above or below target range of participants on cadisegliatin vs placebo'}, {'measure': 'To assess the effects of treatment on the incidence of diabetic ketoacidosis', 'timeFrame': '26 weeks', 'description': 'Number of events of diabetic ketoacidosis participants on cadisegliatin vs placebo'}, {'measure': 'To assess the effects of treatment on insulin dosing', 'timeFrame': '18 weeks', 'description': 'Change from baseline in average daily total insulin on cadisegliatin vs placebo'}, {'measure': 'To assess the effects of treatment on body weight', 'timeFrame': '26 weeks', 'description': 'Change from baseline in mean body weight'}, {'measure': 'To assess the incidence of treatment emergent adverse events', 'timeFrame': '26 weeks', 'description': 'Number of treatment emergent adverse events with cadisegliatin vs placebo'}, {'measure': 'To assess the incidence of treatment emergent adverse events leading to discontinuation', 'timeFrame': '26 weeks', 'description': 'Number of treatment emergent adverse events leading to discontinuation with cadisegliatin vs placebo'}, {'measure': 'To assess the incidence of adverse events of special interest', 'timeFrame': '26 weeks', 'description': 'Number of adverse events of special interests with cadisegliatin vs placebo'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 1']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://t1dexchange.org/vtv-therapeutics-study/', 'label': 'T1D Exchange prescreening website'}]}, 'descriptionModule': {'briefSummary': 'This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.', 'detailedDescription': 'Study TTP399-302 is a 26-week, Phase 3 trial designed to measure the relative efficacy of adjunctive treatment with cadisegliatin to reduce the incidence of Level 2 or Level 3 hypoglycemia in participants with Type 1 Diabetes Mellitus compared to placebo (insulin alone) over 26 weeks of continuous therapy.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Individuals ≥18 years\n* Diagnosed T1DM with a minimum of 5 years since diagnosis\n* Has had at least 1 hypoglycemic event of Level 2 (glucose level \\<54 mg/dL or \\<3 mmol/L, \\[CGM or SMBG confirmed\\]) or Level 3 (defined as a severe hypoglycemia with altered mental state and/or physical status requiring assistance) in the last 2 months prior to Screening\n* HbA1c value of \\<9.5% at Screening\n* Is currently on CSII (closed-loop systems are prohibited) or is on MDI for at least 6 months prior to the Screening Visit and is willing to stay on same type of insulin treatment and the current mode of insulin administration (CSII or MDI injection treatments) for the duration of the study\n* Must have used a CGM device for at least 3 consecutive months prior to Screening\n\nExclusion Criteria:\n\n* Has T2DM, monogenic diabetes, maturity-onset diabetes of the young, other unusual or rare forms of diabetes mellitus, or diabetes resulting from a secondary disease\n* Has been hospitalized for DKA within 3 months prior to Screening\n* Has uncontrolled hypothyroidism or hyperthyroidism\n* History of eating disorder within the last 2 years such as anorexia, bulimia, diabulimia or neglecting to give insulin to manipulate weight\n* Has an active or untreated malignancy, or has been in remission from malignancy for ≤5 years except well-treated basal cell or squamous cell skin cancer or cervical cancer in situ\n* Has used any of the following medications within the specified time periods - any non-insulin anti-diabetic therapies, e.g., sodium glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, or pramlintide, alpha-glucosidase inhibitors, or glucose-dependent insulinotropic polypeptide agonists) or weight loss medications within 30 days prior to the Screening\n* Has used a hybrid closed-loop system (e.g., Medtronic 670G, Omnipod 5, or Tandem X2 with control IQ) or Do-It-Yourself looping within the last 30 days prior to the Screening Visit, and agrees to not start hybrid closed-loop systems or Do-It-Yourself looping during the study.\n* Has an estimated glomerular filtration rate (eGFR) \\<30 mL/min/1.73 m2 utilizing the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at Screening\n* Has uncontrolled hypertension prior to Screening'}, 'identificationModule': {'nctId': 'NCT06334133', 'acronym': 'CATT1', 'briefTitle': 'Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes', 'organization': {'class': 'INDUSTRY', 'fullName': 'vTv Therapeutics'}, 'officialTitle': 'Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 26-Week Double-Blind, Randomized, Placebo-Controlled Phase 3 Study', 'orgStudyIdInfo': {'id': 'TTP399-302'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cadisegliatin: 26 Week Double Blind Treatment Period - 800 mg QD', 'description': 'The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 26-week treatment period. Insulin is adjunctive therapy.', 'interventionNames': ['Drug: Cadisegliatin 800 mg QD']}, {'type': 'EXPERIMENTAL', 'label': 'Cadisegliatin: 26 Week Double Blind Treatment Period - 800 mg BID', 'description': 'The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 26-week treatment period. Insulin is adjunctive therapy.', 'interventionNames': ['Drug: Cadisegliatin 800 mg BID']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo: 26 Week Double Blind Treatment Period', 'description': 'The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 26-week treatment period. Insulin is adjunctive therapy.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Cadisegliatin 800 mg QD', 'type': 'DRUG', 'otherNames': ['TTP399'], 'description': 'Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.', 'armGroupLabels': ['Cadisegliatin: 26 Week Double Blind Treatment Period - 800 mg QD']}, {'name': 'Cadisegliatin 800 mg BID', 'type': 'DRUG', 'otherNames': ['TTP399'], 'description': 'Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.', 'armGroupLabels': ['Cadisegliatin: 26 Week Double Blind Treatment Period - 800 mg BID']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo (insulin alone)', 'armGroupLabels': ['Placebo: 26 Week Double Blind Treatment Period']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85260', 'city': 'Scottsdale', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Rohit Dwivedi, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Scottsdale Clinical Trials', 'geoPoint': {'lat': 33.50921, 'lon': -111.89903}}, {'zip': '72205', 'city': 'Little Rock', 'state': 'Arkansas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Priyantha N Wijewardane, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Baptist Health Center for Clinical Research', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'zip': '92025', 'city': 'Escondido', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Timothy Bailey, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Advanced Metabolic Care & Research Institute, Inc. (AMCR)', 'geoPoint': {'lat': 33.11921, 'lon': -117.08642}}, {'zip': '92078', 'city': 'Fountain Valley', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Babak Ghavami, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'MD Studies, Inc', 'geoPoint': {'lat': 33.70918, 'lon': -117.95367}}, {'zip': '92647', 'city': 'Huntington Beach', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Chris Tsimerekis, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'AME Clinical Research', 'geoPoint': {'lat': 33.6603, 'lon': -117.99923}}, {'zip': '90301', 'city': 'Inglewood', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Soheil Heckmat, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': '310 Clinical Research', 'geoPoint': {'lat': 33.96168, 'lon': -118.35313}}, {'zip': '92037', 'city': 'La Jolla', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Athena Philis-Tsimikas, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Scripps Whittier Diabetes Institute', 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}}, {'zip': '95355', 'city': 'Modesto', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Gopika Gangupantula, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Paradigm Clinical Research - Modesto', 'geoPoint': {'lat': 37.6391, 'lon': -120.99688}}, {'zip': '92108', 'city': 'San Diego', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Schafer Broeder, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Paradigm Clinical Research Centers LLC', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '92120', 'city': 'San Diego', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'John D Beckes, DO, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Acclaim Clinical Research', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '91307', 'city': 'West Hills', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Hessam Aazami, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Focus Clinical Research', 'geoPoint': {'lat': 34.19731, 'lon': -118.64398}}, {'zip': '80113', 'city': 'Englewood', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Lori Gerard, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Denver Endocrinology Diabetes and Thyroid Center', 'geoPoint': {'lat': 39.64777, 'lon': -104.98776}}, {'zip': '33756', 'city': 'Clearwater', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Alexander J Williams, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'BayCare Health Systems', 'geoPoint': {'lat': 27.96585, 'lon': -82.8001}}, {'zip': '33024', 'city': 'Cooper City', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Lorena Lewy-Alterbaum, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'ALL Medical Research, LLC', 'geoPoint': {'lat': 26.05731, 'lon': -80.27172}}, {'zip': '33169', 'city': 'Miami Gardens', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jeremy Bleicher, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Excellence Medical and Research', 'geoPoint': {'lat': 25.94204, 'lon': -80.2456}}, {'zip': '33413', 'city': 'West Palm Beach', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Barry Horowitz, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Metabolic Research Institute, Inc', 'geoPoint': {'lat': 26.71534, 'lon': -80.05337}}, {'zip': '30318', 'city': 'Atlanta', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Bruce Bode, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Atlanta Diabetes Associates', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '30114', 'city': 'Canton', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jason A Berner, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'East Coast Institute for Research, LLC', 'geoPoint': {'lat': 34.23676, 'lon': -84.49076}}, {'zip': '31904', 'city': 'Columbus', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Steven Leichter, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centricity Research - Columbus', 'geoPoint': {'lat': 32.46098, 'lon': -84.98771}}, {'zip': '31210', 'city': 'Macon', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Thomas C Jones, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'The Jones Center Clinical Research, LLC', 'geoPoint': {'lat': 32.84069, 'lon': -83.6324}}, {'zip': '30076', 'city': 'Roswell', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'John "Chip" Reed, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Endocrine Research Solutions, Inc', 'geoPoint': {'lat': 34.02316, 'lon': -84.36159}}, {'zip': '50265', 'city': 'West Des Moines', 'state': 'Iowa', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Anuj Bhargava, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Iowa Diabetes and Endocrinology Research Center', 'geoPoint': {'lat': 41.57721, 'lon': -93.71133}}, {'zip': '66219', 'city': 'Lenexa', 'state': 'Kansas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Thomas R Kreamer, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Johnson County Clin-Trials, LLC', 'geoPoint': {'lat': 38.95362, 'lon': -94.73357}}, {'zip': '48334', 'city': 'Farmington Hills', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Lowel Richard Schmeltz, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Profound Research LLC', 'geoPoint': {'lat': 42.48531, 'lon': -83.37716}}, {'zip': '89109', 'city': 'Las Vegas', 'state': 'Nevada', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Robby Quintos, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Excel Clinical Research', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '89128', 'city': 'Las Vegas', 'state': 'Nevada', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Samer Nakhle, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Palm Research Center', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '89436', 'city': 'Sparks', 'state': 'Nevada', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Nitesh Kuhadiya, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Vector Clinical Trials', 'geoPoint': {'lat': 39.53491, 'lon': -119.75269}}, {'zip': '10461', 'city': 'The Bronx', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Preeti Kishore, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Jacobi Medical Center', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '27514', 'city': 'Chapel Hill', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Klara Klein, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of North Carolina at Chapel Hill', 'geoPoint': {'lat': 35.9132, 'lon': -79.05584}}, {'zip': '27834', 'city': 'Greenville', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Mark L Warren, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Physician's East PA", 'geoPoint': {'lat': 35.61266, 'lon': -77.36635}}, {'zip': '28557', 'city': 'Morehead City', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Kathryn Jean Lucas, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Lucas Research, Inc', 'geoPoint': {'lat': 34.72294, 'lon': -76.72604}}, {'zip': '44718', 'city': 'Canton', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Arvind Y Krishna, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Diabetes & Endocrinology Associates of Stark County, Inc', 'geoPoint': {'lat': 40.79895, 'lon': -81.37845}}, {'zip': '94520', 'city': 'Concord', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Yeran Bao, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'John Muir Physician Network Clinical Research Center', 'geoPoint': {'lat': 39.02201, 'lon': -84.08021}}, {'zip': '97504', 'city': 'Medford', 'state': 'Oregon', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Sarah Smiley, DO, FACP', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Velocity Clinical Research - Medford', 'geoPoint': {'lat': 42.32652, 'lon': -122.87559}}, {'zip': '19104', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Michael R Rickles, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Pennsylvania Perelman Center for Advanced Medicine', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '78731', 'city': 'Austin', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Thomas Belvins, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Texas Diabetes and Endocrinology, P.A', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '75230', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Dan Lender, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Velocity Clinical Research - Dallas', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75149', 'city': 'Mesquite', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Sumana Gangi, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Southern Endocrinology Associates PA', 'geoPoint': {'lat': 32.7668, 'lon': -96.59916}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Mark S Kipnes, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Diabetes & Glandular Disease Clinic, P.A.', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '78231', 'city': 'Shavano Park', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Michelle Welch, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Consano Clinical Research', 'geoPoint': {'lat': 29.58495, 'lon': -98.55252}}, {'zip': '84405', 'city': 'Ogden', 'state': 'Utah', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'Advanced Research Institute - Ogden', 'geoPoint': {'lat': 41.223, 'lon': -111.97383}}, {'zip': '84107', 'city': 'Salt Lake City', 'state': 'Utah', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'David C Larsen, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Wasatch Clinical Research, LLC', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '98109', 'city': 'Seattle', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Subbulaxmi Trikudanathan, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Washington Diabetes Institute', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}], 'centralContacts': [{'name': 'Jennifer Freeman, Ph.D.', 'role': 'CONTACT', 'email': 'clinicaltrials@vtvtherapeutics.com', 'phone': '(336) 888-0435'}], 'overallOfficials': [{'name': 'Thomas Strack, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'vTv Therapeutics'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'vTv Therapeutics', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}